Zenas BioPharma Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Zenas BioPharma is a clinical-stage biotechnology company focused on autoimmune diseases with a global development approach. It combines an experienced leadership team with a disciplined process for identifying, acquiring, and advancing product candidates from around the world to deliver potential clinical benefits for patients. The company is advancing two late-stage programs—obexelimab and orelabrutinib—alongside earlier-stage candidates such as ZB021 and ZB022.

Headquartered in Waltham, Massachusetts, Zenas operates as a mid-sized biopharma company. Obexelimab is a bifunctional antibody that targets CD19 and FcγRIIb to modulate B cells without depletion, while orelabrutinib is an oral BTK inhibitor with activity in the central nervous system. In May 2026, Zenas partnered with Innocarepharma to develop ICP-054, an IL-17AA/AF inhibitor.

Sign up for free to view info

Company overview Employee directory